Bristol-Myers Squibb (NYSE:BMY) Shares Up 1% - Still a Buy?

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) was up 1% during trading on Thursday . The stock traded as high as $47.57 and last traded at $47.45. Approximately 1,543,939 shares changed hands during trading, a decline of 88% from the average daily volume of 13,095,417 shares. The stock had previously closed at $46.97.

Analyst Ratings Changes

Several equities research analysts have recently commented on BMY shares. Jefferies Financial Group decreased their price objective on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. UBS Group decreased their price objective on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a report on Friday, April 11th. William Blair restated a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Argus upgraded Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Finally, Cantor Fitzgerald restated a "neutral" rating and set a $55.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $58.00.

Bristol-Myers Squibb Stock Performance

The company has a 50-day simple moving average of $50.49 and a two-hundred day simple moving average of $55.39. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The firm has a market cap of $98.21 billion, a PE ratio of -10.92, a PEG ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The business had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. During the same quarter in the previous year, the firm earned ($4.40) earnings per share. The business's revenue was down 5.6% on a year-over-year basis. As a group, equities research analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were given a dividend of $0.62 per share. The ex-dividend date was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.14%. Bristol-Myers Squibb's dividend payout ratio is presently 92.88%.

Insider Activity

In other news, EVP Samit Hirawat purchased 4,250 shares of the company's stock in a transaction dated Friday, April 25th. The shares were purchased at an average price of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president now directly owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.09% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Pinney & Scofield Inc. purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth about $25,000. Park Square Financial Group LLC purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth about $26,000. Fairway Wealth LLC purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth about $28,000. Transce3nd LLC purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth about $28,000. Finally, Global Wealth Strategies & Associates lifted its holdings in shares of Bristol-Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 275 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.